May 28, 2009 - GE Healthcare (GE) and Fujifilm signed a strategic alliance to co-develop new biomolecular imaging systems based on Fujifilm’s CCD and laser-based imaging technology, which GE will market under its own brands to the life science research and drug discovery markets worldwide.
The deal primarily aims to develop application-specific systems and will also allow GE to market Fujifilm's top-spec FLA-9000 and FLA-7000 multipurpose imaging scanners. These will be offered as an extension to its Typhoon family of variable-mode imagers for phosphor and fluorescence applications. Fujifilm’s LAS 4000 platform, a luminescent image analyzer to feature the company’s proprietary CCD technology, will be marketed by GE through its existing ImageQuant product family.
For more information: www.gehealthcare.com
November 21, 2025 
